Preferred Label : sipuleucel-T;

MeSH note : consists of CD54-positive PA2024-loaded antigen presenting cells with admixtures of monocytes, macrophages, and B and T cells; proposed prostate cancer vaccine;

CISMeF synonym : APC 8015; provenge;

MeSH hyponym : APC8015; APC-8015;

Is substance : O;

UNII : 8Q622VDR18;

Détails


Consulter ci-dessous une sélection des principales ressources :

Vous pouvez consulter :


https://www.ema.europa.eu/medicines/human/EPAR/Provenge
2013
United Kingdom
French
English
sipuleucel-T
sipuleucel-T
sipuleucel-T
drug approval
europe
treatment outcome
adult
prostatic neoplasms
neoplasm metastasis
summary of product characteristics
package leaflet
drug evaluation
syndication feed
immunotherapy
survival analysis
infusions, intravenous
leukapheresis
product surveillance, postmarketing
prostatic acid phosphatase
prostatic neoplasms
antigen-presenting cells
protein tyrosine phosphatases
tissue extracts
tissue extracts

---
https://www.cadth.ca/sites/default/files/pdf/E0037_Sipuleucel-T_prostate_cancer_cetap_f.pdf
https://www.cadth.ca/sites/default/files/pdf/E0037_Sipuleucel-T_prostate_cancer_cetap_e.pdf
2007
Canada
English
French
tissue extracts
prostatic neoplasms
prostatic neoplasms
immunotherapy, active
treatment outcome
canada
tissue extracts
tissue extracts
cancer vaccines
cancer vaccines
cancer vaccines
clinical trials as topic
Evidence-Based medicine
survival analysis
infusions, intravenous
sipuleucel-T
sipuleucel-T
sipuleucel-T
sipuleucel-T
drug evaluation

---
Nous contacter.
27/07/2025


[Accueil] [Haut de page]

© CHU de Rouen. Toute utilisation partielle ou totale de ce document doit mentionner la source.